SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?


To: Wizzer who wrote (260)6/9/1998 7:27:00 PM
From: Anthony Wong  Respond to of 1722
 
FDA, Pfizer Say There Is No Direct Link Between Viagra, 16 Deaths
June 09, 1998 3:58 PM

WASHINGTON -(Dow Jones)- The Food and Drug
Administration and Pfizer Inc. said Tuesday they
continue to back the impotence drug Viagra, saying the
deaths of 16 men taking the drug haven't been linked to
the blockbuster pill.

FDA spokeswoman Susan Cruzan said the deaths don't
change the agency's opinion about Viagra. "We believe
the drug is still safe and effective for the patient
population it is intended for.

"We cannot identify a direct link betwen Viagra and
these reports of deaths," Cruzan said. "We will continue
to monitor these and other reports for trends that show
any change in the drug safety profile just as we do for
any other drug."

An additional eight people died during the drug's clinical
trials.

Of the 16 postmarketing reports, some contain
incomplete information, and Cruzan said the deaths
could have been the result of an underlying disease.

The 16 deaths are listed on the agency's World Wide
Web site. According to information at the site, most of
the men had suffered from conditions ranging from
diabetes to congestive heart failure to high blood
pressure, among others. Most of the men were in their
60s and 70s, although one man was 48 and another was
80.

In several of the cases, the reports said the men
collapsed during or shortly after sexual activity.

"We also have to put this into perspective with the
number of prescriptions written for Viagra," Cruzan said.

Pfizer spokesman Andy McCormick said 1.7 million
prescriptions have been written since the FDA cleared
the drug March 27. He more than one million men have
used the drug and 80% are over age 50.

"There is guidance to the physicians on the label that
says in this age population a thorough medical evaluation
should be done because sexual intercourse is a form of
physical exertion," McCormick said.

Last week Pfizer sent letters to 600,000 doctors who
may prescribe Viagra explaining that the drug shouldn't
be given to patients taking nitrates. Of the 16 deaths
reported to the FDA, two patients were given
nitroblycerin after experiencing chest pains.

When a patient dies or has a complication while using a
drug, the FDA requires companies to report the case to
the agency within 15 days.

The company is continuing to study Viagra in different
groups of patients, McCormick said.

Since Viagra hit pharmacy shelves in April, sales have
totaled more than $130 million, according to
Scott-Levin, a health-care marketing company.

Dr. Barney Rosen, an analyst who follows the
pharmaceutical industry for Argus Research Corp., said
he doesn't think the reports of deaths will stop men from
asking for Viagra.

"Sex sells," Rosen said. "People will say 'it's not going to
hurt me.'"

Men will discover that Viagra doesn't work for
everyone, he said. The company estimates it works for
about 70% of impotent men.

Other impotence products will eventually benefit from
Viagra's success.

"Viagra is getting people out of the woodwork," Rosen
said. "People who can't use it because they have heart
conditions or people it doesn't work in will turn to the
other products."
-Otesa Middleton; 202-862-6654

Copyright (c) 1998 Dow Jones & Company, Inc.

All Rights Reserved.




To: Wizzer who wrote (260)6/9/1998 7:28:00 PM
From: Anthony Wong  Respond to of 1722
 
Pfizer Shrs Rise Amid Talk Of Deaths Of Viagra Takers
June 09, 1998 4:00 PM

NEW YORK (Dow Jones)--Investors continued to bid
up shares of Pfizer Inc. (PFE), undeterred by reports of
more deaths of men taking Viagra.

The Food and Drug Administration now says that 16
men have died while taking the impotence pill, but that
none of those deaths has been linked to the blockbuster
drug. The FDA first reported last month that it was
investigating the deaths of six men who reportedly were
taking Viagra.

About 1.7 million prescriptions have been written since
the FDA cleared the drug March 27.

Shares of Pfizer rose 4 1/16, or 3.7%, to 112 1/2
Tuesday on composite volume of 6 million, compared
with average daily volume of 5.4 million.

Analysts said investors have no reason to be
concerened. The FDA continues to say it believes
Viagra is safe and effective for the patient population for
which it is intended. And Pfizer continues to do a good
job warning against mixing Viagra with nitrates, a
common class of heart medication, said Steve Lisi, an
analyst with Mehta Partners.

Indeed, since Viagra hit pharmacy shelves in April, sales
have totaled more than $130 million, according to Scott
Levin, a health care marketing company.

People with erectile dysfunction also frequently suffer
from other serious underlying health conditions, such as
diabetes or cardiovascular disease. Diabetes, prostate
cancer and other conditions can lead to impotence.
-By Jennifer Fron Mauer; 201-938-5287;
jennifer-fron.mauer@cor.dowjones.com




To: Wizzer who wrote (260)6/9/1998 7:32:00 PM
From: Anthony Wong  Respond to of 1722
 
Bloomberg - Pfizer's Viagra Not Direct Cause in Deaths, FDA Says (Update6)

Bloomberg News
June 9, 1998, 2:07 p.m. PT

Pfizer's Viagra Not Direct Cause in Deaths, FDA Says (Update6)
(Closes shares, changes wording in first and last
paragraphs.)

Washington, June 9 (Bloomberg) -- Pfizer Inc.'s impotence
drug Viagra hasn't been found to be the direct cause of death in
any of the 16 reports involving users of the drug who died, the
Food and Drug Administration said, sending shares soaring.

Most of the men in the reports were between the ages of 60
and 80, and had a history of cardiovascular problem, according to
reports listed by the FDA in an update on its monitoring of the
Pfizer drug.

''They're not related directly to use of the drug,'' said
Susan Cruzan, a spokeswoman for the FDA. ''They do not change the
FDA's perspective on the use or safety of the drug.''

Pfizer shares rose 4 to close at 112 7/16 today, following
news of the reports. More than 6.4 million shares changed hands,
making Pfizer one of the 15 most actively traded stocks in the
U.S. The rally boosted Pfizer shares above where they were
trading three weeks ago, before the first reports of deaths among
the drug's users sent shares plunging.

The FDA will continue to monitor and investigate all new
reports as they are submitted, as it does with all drugs and
medical products it approves, Cruzan said. If some direct link
between the drug and these deaths or future deaths emerges, the
FDA will take action, she said.

Medical experts said they were not surprised by the number
of deaths. Many of the medical conditions related to impotence --
such as diabetes, high blood pressure and smoking -- also put a
patient at a higher risk for heart attacks and other problems,
whether patients are taking Viagra or not, said Ira Sharlip, a
practicing urologist in San Francisco, California.

''It doesn't seem to me to be out of line for the number of
deaths for that group, whether they are taking Viagra or not,''
Sharlip said.

Warnings on Label

The label for the impotence pill already warns against
mixing Viagra with a common class of heart drugs known as
nitrates. At least three of the deaths in the reports involved
men who were treated with nitroglycerin, a nitrate drug, after
they took Viagra and experienced heart problems.
Viagra is also among the some 25 drugs known to have
potentially dangerous reactions when taken with the heart drug
Posicor, made by Roche Holding AG, which withdrew it from the
market yesterday.

The drug labeling also warns doctors to assess how able
their patients may be to undertake the stress of sexual activity.

About 1.7 million prescriptions for the drug have been
filled, said Andrew McCormick, a spokesman for Pfizer.
The reports so far do not indicate any new side effects of the
drug, he said.

''Everything has been in line with the clinical
experience,'' McCormick said.

In one case report, a 74-year-old man taking four drugs to
treat his high blood pressure, diabetes and cancer died the
morning after taking Viagra. In another case, a 73-year-old man
died during sexual activity after taking a second dose of the
drug. The man had a history of high blood pressure, the report
said.

Worth the Risk?

Patients who are elderly or who have heart problems are at
greater risk when they engage in the physical activity required
by sex. Still, the risks are not alarming, said Sharlip, who also
sits on the American Urological Association's impotence guideline
committee.

''Even though there is an increase in the risk, the risk is
still very small,'' he said. ''I think it makes sense to tell
people that and to then let them make the choice as to whether
having sex is worth that risk.''

In the more than 400 patients he has treated with Viagra,
Sharlip has yet to find a patient who was deterred by the risk of
having sex, he said.

Still the record-breaking popularity of the drug has played
some role in the number of incidents because it is likely many
men are taking the drug who for a number of reasons should not be
because of poor health or conflicting medications, Lisi said.

''These are small numbers in contrast to the amount of
patients using the drug,'' said Steve Lisi, an analyst with Mehta
Partners. Still, ''we're probably going to continue to see this
as people use this drug like aspirin,'' he said.

Reports of adverse or even fatal events linked to a drug are
collected through the FDA's MedWatch system, designed to ensure
all reports of problems will be seriously addressed. MedWatch
allows doctors, companies, consumers or pharmacists to file
information on possible side effects found with a drug. However,
these reports may be second- or even third-hand and are not
considered confirmed until they have been evaluated by the
agency.

In addition, more than one report may be filed for a
patient, which may make it appear more people died than was the
case. At least four different initial reports were filed for one
63 year-old man who died after taking Viagra. That death is only
counted once among the 16 now listed by the FDA, though.

The FDA sorts the reports to eliminate duplicates and is now
posting them on a page on its home page to make the numbers
publicly available, Cruzan said.

The FDA has held its position since the earliest death
reports, saying that any relationship between the deaths and the
drug is unproven, she said.

--Kristin Reed in Washington (202) 624-1858 with reporting by